Medtronic (1MDT) AI Stock Analysis

Company Guidance

For fiscal year '27, Medtronic raised organic revenue growth guidance to 7.25% to 7.75% and expects roughly 6% organic revenue growth in Q2; foreign exchange is expected to be a roughly $50 million to $150 million headwind for the full year and an approximate $25 million to $75 million headwind in 2Q. The company expects operating profit to grow approximately 10%, with operating margin expanding approximately 50 basis points year-over-year, and raised fiscal '27 EPS guidance to $5.94 to $6, with Q2 EPS expected in the range of $1.32 to $1.34 and a roughly neutral impact from foreign exchange. CAS is expected to grow 2.5x the market for the full year and north of 3x the market in Q2, with the market in the mid-teens; Hugo is expected to surpass 50,000 completed procedures by the end of the fiscal year with procedure growth continuing at more than twice the market rate, while the transradial catheter remains on track to launch in the second half of this fiscal year, Neurovascular is expected to reach mid-single digit growth in the back half of the year, ACM is expected to normalize as Medtronic moves through 2027, acquisitions are expected to contribute over $150 million to inorganic growth in fiscal year '27, and the MiniMed separation is intended to close prior to fiscal year-end.